{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-26-000007","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.738456+00:00","generated_at":"2026-05-15T23:26:48.928676+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amphastar Q4 revenue $183.1M, down 1.8% YoY; GAAP EPS $0.51 vs $0.74","bullets":["Full year 2025 net revenue $719.9M, down 1.6% YoY from $732.0M.","GAAP net income Q4 $24.4M ($0.51 diluted EPS) vs $38.0M ($0.74) in Q4 2024; FY $98.1M ($2.03) vs $159.5M ($3.06).","Adjusted non-GAAP net income Q4 $34.2M ($0.73 diluted EPS) vs $47.2M ($0.92) a year ago.","CEO cites BAQSIMI double-digit growth and FDA approvals of iron sucrose and teriparatide injections as positives.","Three novel peptides and a synthetic corticotropin compound added to pipeline for oncology, ophthalmology, and immunology."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-26-000007","json":"https://secwatch.observer/filing/0001297184-26-000007.json","markdown":"https://secwatch.observer/filing/0001297184-26-000007.md","text":"https://secwatch.observer/filing/0001297184-26-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718426000007/0001297184-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718426000007/amph-20260226x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:26:48.928676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}